TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

about

Telomere Maintenance Mechanisms in Cancer.

P2860

Q55443450-D6057651-4965-43A4-95E0-073FCAA1D821

P2860

TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

Item

http://www.wikidata.org/entity/Q38774845

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

TERT promoter mutation status ...... as of the upper urinary tract.

@en

type

Item

label

TERT promoter mutation status ...... as of the upper urinary tract.

@en

prefLabel

TERT promoter mutation status ...... as of the upper urinary tract.

@en

P1476

TERT promoter mutation status ...... as of the upper urinary tract.

@en

P2093

Adeboye O Osunkoya

http://www.w3.org/2001/XMLSchema#string

Antonio Lopez-Beltran

http://www.w3.org/2001/XMLSchema#string

Darrell D Davidson

http://www.w3.org/2001/XMLSchema#string

Gregory T MacLennan

http://www.w3.org/2001/XMLSchema#string

Hristos Z Kaimakliotis

http://www.w3.org/2001/XMLSchema#string

Lee Ann Baldridge

http://www.w3.org/2001/XMLSchema#string

Liang Cheng

http://www.w3.org/2001/XMLSchema#string

Mingsheng Wang

http://www.w3.org/2001/XMLSchema#string

Puay-Hoon Tan

http://www.w3.org/2001/XMLSchema#string

Robert E Emerson

http://www.w3.org/2001/XMLSchema#string

P2860

PAX 8 expression in non-neoplastic tissues, primary tumors, and metastatic tumors: a comprehensive immunohistochemical study

A comprehensive analysis of PAX8 expression in human epithelial tumors

Highly recurrent TERT promoter mutations in human melanoma

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.

TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas.

p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma.

Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression

Use of p40 and p63 immunohistochemistry and human papillomavirus testing as ancillary tools for the recognition of head and neck sarcomatoid carcinoma and its distinction from benign and malignant mesenchymal processes.

The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.

TERT promoter mutations and TERT mRNA but not FGFR3 mutations are urinary biomarkers in Han Chinese patients with urothelial bladder cancer.

P304

705-714

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/FON-2016-0414

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Sean R. Williamson

Rodolfo Montironi

P577

2017-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28052688

http://www.w3.org/2001/XMLSchema#string

TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

about

P2860

P2860

TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698